erythropoietin and cancer: the unintended consequences of anemia correction
Clicks: 333
ID: 195100
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
333 views
39 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #67 of 644 articles by views in sudebno-meditsinskaia ekspertiza
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and medical opinion evolved, beginning with the discovery of an effect on endothelial cell growth in vitro and the identification of EPO receptors on neuronal cells. We now know that EPO is a pleiotropic growth factor that exhibits an anti-apoptotic action on numerous cells and tissues, including malignant ones. In this article, we present a short discussion of EPO, receptors involved in EPO signal transduction, and their action on non-hematopoietic cells. This is followed by a more detailed presentation of both pre-clinical and clinical data that demonstrate EPO’s action on cancer cells as well as tumor angiogenesis and lymphangiogenesis. Clinical trials with reported adverse effects of erythropoiesis stimulating agents (ESAs) as well as clinical studies exploring the prognostic significance of EPO and EPOR expression in cancer patients are reviewed. Lastly, we address the use of EPO and other ESAs in cancer patients.
| Reference Key |
edebeljak2014frontierserythropoietin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Nataša eDebeljak;Peter eSolar;Arthur John Sytkowski |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2014 |
| DOI |
10.3389/fimmu.2014.00563
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.